Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged Lovasa
Amarin: What does Amarin’s reply appellate brief say?

Amarin’s appeal of the district court’s decision invalidating the Marine patents is now fully briefed. Amarin’s reply brief is strong, but does it tip the odds in favor of Amarin prevailing on the appeal?

Read More
Markman AdvisorsAmarin Pharma, Amarin, $AMRN, AMRN, vacepa, Hikma, Dr. Reddy's, Federal Circuit, patent, hypertriglyceridemia, triglycerides, LDL-C, Dr. Bhatt, Bhatt, EPA, Epadel, Lovasa, Heinecke, Zachary Silbersher, Silbersher Comments
Can Amarin’s patents protect Vascepa from generics?

Amarin Pharmaceuticals ($AMRN) will be going to trial soon to protect Vascepa® against generic competition.  Amarin has asserted 15 claims from six patents against ANDAs filed by Hikma, Dr. Reddy’s and Teva.  What are the issues to be addressed at trial?

Read More
Markman AdvisorsAmarin, Amarin Pharmaceuticals, $AMRN, AMRN, Vascepa, Hikma, Dr. Reddy's, Teva, $TEVA, MARINE, REDUCE-IT, generic, patent, Hatch-Waxman, Nevada, District of Nevada, hypertriglyceridemia, triglycerides, Epadel, Lovasa, LDL-C, EPA, Apo-B, apolipoprotein B, Zachary Silbersher, Silbersher Comments